CooperSurgical Announces the Donation of More Than 300 Cord Blood Samples and Additional Funding to Support Ongoing Stem Cell Research at the University of Toronto

TRUMBULL, Conn. — CooperSurgical Affiliate donates hundreds of cord blood units and additional funding to advance stem cell research led by Dr. Ian Rogers at the University of Toronto.

The donation comes from the Victoria Angel Registry of Hope (VAR), a non-profit charitable public cord blood bank that operated in association with CooperSurgical’s Cells for Life division, and was dedicated to collecting and preserving publicly donated cord blood units for both medical treatment and research.

By transferring these valuable biological resources and financial support, CooperSurgical is helping ensure that this important legacy continues to benefit the scientific and medical communities.

“Through this donation, we are proud to extend the impact of the Victoria Angel Registry of Hope and support critical research that has the potential to transform patient care,” said Holly Sheffield, President of CooperSurgical. “Guided by our mission of accelerating what’s possible for women, babies, and families, CooperSurgical remains committed to advancing innovation and helping improve outcomes through meaningful collaboration.”

Dr. Rogers, a leading researcher in stem cell biology, will oversee the integration and application of these cord blood units to further research in regenerative medicine and emerging therapeutic approaches. This work is expected to contribute to new insights into the potential of stem cells to transform patient care and advance next-generation treatments.

“This donation represents an important step forward in advancing stem cell research and its clinical potential. Access to high-quality cord blood units is essential to supporting the scientific work that will shape the next future therapies,” said Dr. Rogers. “We are grateful to CooperSurgical for enabling continued research that may lead to new treatments and improved patient outcomes.”

Cord blood is a rich source of stem cells with the ability to develop into different types of blood and immune cells, making it a critical resource for research into a wide range of diseases and medical conditions, including blood disorders, immune deficiencies, and regenerative therapies.

Through initiatives like this, CooperSurgical continues to support scientific advancement and reinforce its commitment to improving healthcare outcomes on a global scale.

CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most in life. CooperSurgical is at the forefront of delivering innovative assisted reproductive technology (ART) and genomic solutions that enhance the work of ART professionals to the benefit of families. We currently offer over 600 clinically relevant medical devices to women’s healthcare providers, including testing and treatment options.

CooperSurgical is a wholly owned subsidiary of CooperCompanies (Nasdaq: COO). CooperSurgical, headquartered in Trumbull, CT, produces and markets a wide array of products and services for use by women’s healthcare clinicians.

CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.

© 2026 CooperSurgical, Inc. All rights reserved. C-GL-CSI-000181 06/2026

Contacts

CooperSurgical